AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34941035
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (Control)
Trial: 32572776
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg, daily) and Fuzheng Huayu Tablet (1.6 g, 3 times a day)
Trial: 32572776
Drug: Entecavir (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir (0.5 mg, daily) and Fuzheng Huayu Tablet placebo (1.6 g, 3 times a day)
Trial: 34522082
Drug: Phenylephrine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine IV bolus (40, 50, 60, 70, or 80 µg)
Trial: 34522082
Drug: Phenylephrine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine IV bolus (70 µg)
Trial: 34522082
Drug: Phenylephrine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine IV bolus (60 µg)
Trial: 34597388
Drug: Propionic acid
RxNorm normalized name: Propionic acid
DrugBank: Propanoic acid (DB03766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionic acid (PA) 500 mg twice daily for 8 weeks
Trial: 33549311
Drug: 150 mg/mL
RxNorm normalized name: urea 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/mL by PFS × 1 SC injection
Trial: 33549311
Drug: 90 mg/mL
RxNorm normalized name: urea 390 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/mL by PFS × 2 SC injections
Trial: 33549311
Drug: 150 mg/mL
RxNorm normalized name: urea 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/mL by AI × 1 SC injection
Trial: 33549311
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg SC delivered by PFS or AI
Trial: 34602393
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells (MSCs) administered as intravenous infusion of marrow‐derived autologous MSCs (1×10^6 to 2×10^6/kg) for 8 weeks
Trial: 34602393
Drug: Acetyl cysteine
RxNorm normalized name: Acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl cysteine (NACys) 600mg orally twice a day for 8 weeks
Trial: 34517747
Drug: Self-stigma reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-stigma reduction programme (psychoeducation, cognitive behavioural therapy and social skills training)
Trial: 34080313
Drug: KMRC011 15
RxNorm normalized name: KMRC011, a flagellin-derived radiation countermeasure
DrugBank: Xempritolimod (DB19412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KMRC011 15 μg
Trial: 34080313
Drug: KMRC011 20
RxNorm normalized name: KMRC011, a flagellin-derived radiation countermeasure
DrugBank: Xempritolimod (DB19412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KMRC011 20 μg
Trial: 34080313
Drug: KMRC011 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KMRC011 (5, 10, 15, and 20 μg)
Trial: 34080313
Drug: KMRC011 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KMRC011 (15 μg and 20 μg)
Trial: 34311300
Drug: Paclitaxel (PTX)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (PTX) 100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of each 49-day cycle
Trial: 34311300
Drug: Docetaxel (DTX)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DTX) 70 mg/m2 on day 1 of each 21-day cycle
Trial: 32992268
Drug: Experiential training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential training (training‐as‐usual plus a one‐session treatment for fear of spiders)
Trial: 35409234
Drug: SSRIs (paroxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (paroxetine or sertraline)
Trial: 35870801
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) training curriculum with four 15-minute monthly didactics on BHAG and MI followed by VR simulations.
Trial: 34405148
Drug: Collagen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen (40 gr/d) plus Fish Oil (10 ml/d)
Trial: 32103410
Drug: STAND (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAND (Motivational Interviewing + Behavior Therapy)
Trial: 32855218
Drug: Automated closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated closed-loop oxygen administration
Trial: 32855218
Drug: Standard manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard manual oxygen administration
Trial: 32644867
Drug: Corneal collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal collagen crosslinking with standard antifungal
Trial: 32644867
Drug: Standard antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antifungal
Trial: 32497491
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable cabotegravir (800 mg given three times at 12 week intervals or 600 mg given five times, administered at one 4 week interval, and every 8 weeks thereafter)
Trial: 35247960
Drug: Peer mentorship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer mentorship (weekly telephone calls with trained mentors for 3 months)
Trial: 34217844
Drug: Dietary Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Astragalus Propinquus schischkin polysaccharides (1000 mg/kg)
Trial: 34217844
Drug: Dietary Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Astragalus Propinquus schischkin polysaccharides (various dosages including 1000 mg/kg)
Trial: 32306935
Drug: Cognitive‐behavioural group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural group therapy (CBGT)
Trial: 34533410
Drug: Sublingual oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual oestradiol hemihydrate (1.3 mg/day) for 12 weeks
Trial: 34533410
Drug: Sublingual oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual oestradiol hemihydrate (1.3 mg/day)
Trial: 34502202
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2, 3000 pulses, 3 pulses/second
Trial: 32326664
Drug: Ubiquinol 200
RxNorm normalized name: ubiquinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol 200 mg/day
Trial: 32326664
Drug: Ubiquinol 100
RxNorm normalized name: ubiquinol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol 100 mg/day
Trial: 32326664
Drug: Ubiquinol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (both doses)
Trial: 34800398
Drug: Teriflunomide (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriflunomide (14 mg equivalent in adults)
Trial: 35709600
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus prednisone (1000 mg abiraterone acetate and 10 mg prednisone daily)
Trial: 32947028
Drug: Aminolevulinic acid/photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminolevulinic acid/photodynamic therapy
Trial: 32947028
Drug: Vehicle/photodynamic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle/photodynamic therapy
Trial: 33370247
Drug: Topical oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oxygen continuously diffused to DFU tissue
Trial: 33370247
Drug: Continuously diffused
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously diffused topical oxygen
Trial: 33175316
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.2% ophthalmic solution
Trial: 32051551
Drug: Primary focal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary focal therapy (HIFU or cryotherapy)
Trial: 35149036
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with edoxaban (a non-vitamin K antagonist oral anticoagulant)
Trial: 35149036
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with edoxaban plus a single antiplatelet agent
Trial: 36373820
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day NWT-03
Trial: 36373820
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day maltodextrin
Trial: 33537760
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation at 0.1 g · kg‐1 body weight · d‐1
Trial: 32128634
Drug: Trifluridine/tipiracil (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC)
Trial: 33837916
Drug: Laboratory sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laboratory sleep monitoring (L)
Trial: 34346852
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) data from the Swedish national quality register (Q‐ECT)
Trial: 32929647
Drug: HCV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV therapy (interferon-based therapy or interferon-free therapy); duration of treatment not specified, but monitoring period is 6 months for cirrhosis patients and 3 months for non-cirrhosis patients.
Trial: 32929647
Drug: HCV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV therapy (treated cohort)
Trial: 32929647
Drug: Untreated cohort
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated cohort (therapy-naïve patients)
Trial: 33848232
Drug: Combined sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sequential vaccination schedule of IPV and bOPV
Trial: 33356044
Drug: Yihechun Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yihechun Capsules (YHC) + Levocarnitine (LC)
Trial: 33497514
Drug: Microneedling combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling combined with NB‐UVB phototherapy and topical latanoprost 0.005%
Trial: 36237565
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days
Trial: 36237565
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days
Trial: 35416973
Drug: Multidose metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose metronidazole 500 mg twice daily for 7 days
Trial: 35416973
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral metronidazole 2 g
Trial: 32776828
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 200 mg/week (TEST)
Trial: 33273042
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with metformin, pioglitazone, and exenatide
Trial: 33273042
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with sequential addition of metformin, glipizide, and insulin
Trial: 32506088
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection paracetamol (1gm) and 0.25% bupivacaine (total 20ml) in scalp block
Trial: 32506088
Drug: 100ml normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml normal saline infusion and 0.25% bupivacaine (20ml) in scalp block
Trial: 34286416
Drug: Interviewer-led telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-led telephone administration of EORTC QLQ-C30
Trial: 34286416
Drug: Paper first
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper first administration of EORTC QLQ-C30
Trial: 34286416
Drug: Phone first
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone first administration of EORTC QLQ-C30
Trial: 32307560
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of methylphenidate (N=29)
Trial: 32428840
Drug: Hypoenergetic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoenergetic diet with 12 hours of fasting daily
Trial: 32126576
Drug: EUS-guided coil
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided coil embolization and cyanoacrylate injection
Trial: 36368940
Drug: PcV 800
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PcV 800 mg × 4 for 5 days
Trial: 36368940
Drug: PcV 1
RxNorm normalized name: Pneumococcal conjugate PCV 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PcV 1 g × 3 for 10 days
Trial: 35193654
Drug: L-carnitine (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3000 mg/day for 7 days)
Trial: 35193654
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dosage and duration as L-carnitine)
Trial: 34536308
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with carfilzomib (27-56 mg/sqm) and dexamethasone (20 mg every second week)
Trial: 33662112
Drug: Overminus spectacle
RxNorm normalized name: econazole nitrate Topical Cream [Spectazole]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overminus spectacle therapy (‐2.50 D for 12 months, then ‐1.25 D for 3 months, followed by nonoverminus spectacles for 3 months)
Trial: 35467300
Drug: ω‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 fatty acid immunonutritional therapy
Trial: 33939973
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical exercise twice a week
Trial: 34538755
Drug: Acebilustat 50
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebilustat 50 mg
Trial: 34538755
Drug: Acebilustat 100
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebilustat 100 mg
Trial: 34538755
Drug: Acebilustat (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebilustat (both doses)
Trial: 32865373
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg monthly subcutaneous injections)
Trial: 36113007
Drug: Compound betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound betamethasone
Trial: 36113007
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no compound betamethasone)
Trial: 36121729
Drug: Novel polymeric
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel polymeric nanoparticle gel
Trial: 36121729
Drug: Commercial gel
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial gel (Opalescence PF)
Trial: 34546534
Drug: AZD5718 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 (60 mg)
Trial: 34546534
Drug: AZD5718 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 (180 mg)
Trial: 34546534
Drug: AZD5718 (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 (360 mg)
Trial: 34546534
Drug: AZD5718 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5718 (600 mg)
Trial: 36440782
Drug: Relatox injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relatox injections
Trial: 36059130
Drug: Etonogestrel and
RxNorm normalized name: Etonogestrel and Ethinyl Estradiol Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel and Levonorgestrel implants
Trial: 34386816
Drug: Vegetable Intervention
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable Intervention (VI) - participants received extra vegetables (≥270 g/d)
Trial: 39209438
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (MT)
Trial: 35080598
Drug: Taper to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper to placebo (taper group)
Trial: 34302145
Drug: Drug repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug repositioning approaches
Trial: 33244458
Drug: Erlotinib 100
RxNorm normalized name: erlotinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 100 mg/d
Trial: 35363627
Drug: Erlotinib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 50 mg/d
Trial: 34364265
Drug: Yacon flour
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yacon flour (25 g daily)
Trial: 32554514
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg plus nab‐paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2
Trial: 33773565
Drug: Levonorgestrel intrauterine
RxNorm normalized name: Levonorgestrel Intrauterine System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel intrauterine system plus metformin (500mg twice daily)
Trial: 33574155
Drug: Intravenous acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acellular sterile filtered amniotic fluid
Trial: 35040600
Drug: Adalimumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (5 mg/kg) administered intraperitoneally for 4 weeks
Trial: 36106542
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 162 mg every week for 24 weeks
Trial: 38985461
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg once daily
Trial: 34319510
Drug: UC-MSC treatment
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC treatment (1-2 × 10^6 per kilogram)
Trial: 35004547
Drug: Online self-control
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-control training added to multidisciplinary obesity treatment (MOT) program
Trial: 35004547
Drug: Sham training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham training added to multidisciplinary obesity treatment (MOT) program
Trial: 34308545
Drug: Cognitive stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation intervention (88 individual sessions, 45 minutes each, twice per week)
Trial: 33651291
Drug: Mycorrhizal treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycorrhizal treatments (Funneliformis mosseae and Claroideoglomus etunicatum)
Trial: 34247160
Drug: Oral frailty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral frailty measures program (12 weeks)
Trial: 616280550
Drug: NRB (non-rebreather
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRB (non-rebreather mask) with flush rate oxygen (>40 L/min)
Trial: 32182353
Drug: Daily cash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cash incentives
Trial: 34378853
Drug: Tapered Implants
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered Implants (TIs)
Trial: 34378853
Drug: Straight Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight Implants (SIs)
Trial: 34378853
Drug: Tapered Implants
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tapered Implants (TIs) and Straight Implants (SIs)
Trial: 32931412
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg iron supplementation
Trial: 32931412
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg iron supplementation
Trial: 35451117
Drug: Water exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water exchange colonoscopy with infused water volume during insertion ≥ 1000 mL
Trial: 33131095
Drug: Revaprazan 200
RxNorm normalized name: Revaprazan
DrugBank: Revaprazan (DB16308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaprazan 200 mg
Trial: 32921535
Drug: 2% Chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Chlorhexidine (CHG) bathing daily during the intervention period (n = 1501)
Trial: 35835631
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and some control of the obstruction